Video Experimental Relacionado
Updated: May 18, 2026
08:27
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
La prevención de la enfermedad de Alzheimer.
1Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. dselkoe@rics.bwh.harvard.edu
Science (New York, N.Y.)
|September 22, 2012
Resumen
Los tratamientos efectivos para la enfermedad de Alzheimer siguen siendo escurridizos. El éxito futuro depende de una intervención más temprana utilizando biomarcadores validados y un aumento de la inversión en investigación.
Área de la Ciencia:
- La neurociencia es la neurociencia.
- Gerontología Gerontología.
- La medicina clínica es la medicina clínica.
Sus antecedentes:
- La investigación de la enfermedad de Alzheimer (EA) se ha extendido durante tres décadas sin un tratamiento definitivo.
- Los ensayos clínicos recientes indican la necesidad de una intervención temprana antes de las etapas de leve a moderada.
Objetivo del estudio:
- Para resaltar la necesidad de una intervención temprana en la enfermedad de Alzheimer.
- Para enfatizar el papel de los biomarcadores en los ensayos de prevención secundaria.
- Para subrayar la necesidad de una mayor inversión y diseños de ensayos refinados.
Principales métodos:
- Análisis de los resultados recientes de ensayos clínicos de la enfermedad de Alzheimer.
- Revisión del progreso en la validación de los biomarcadores presintomáticos para la EA.
- Discusión de la progresión natural de la enfermedad y respuestas terapéuticas.
Principales resultados:
- La validación de biomarcadores presintomáticos permite ensayos de prevención secundaria.
- El análisis de ensayos pasados proporciona información sobre la historia natural de la enfermedad.
- Los enfoques actuales aún no han producido tratamientos efectivos.
Conclusiones:
- El tratamiento temprano de la enfermedad de Alzheimer es crucial para el potencial éxito terapéutico.
- La inversión adicional y el diseño meticuloso del ensayo son esenciales para avanzar en la investigación de AD.
- El desarrollo de biomarcadores es clave para permitir estrategias efectivas de prevención secundaria.
Videos de Conceptos Relacionados
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.